

1 **Neuroinvasive flavivirus pathogenesis is restricted by host genetic factors in**
2 **Collaborative Cross mice, independently of Oas1b**

3

4 Brittany A. Jasperse^{a,*}, Melissa D. Mattocks^{a,*}, Kelsey M. Noll^{a,c}, Martin T. Ferris^b, Mark
5 T. Heise^{a,b}, Helen M. Lazear^{a#}

6

7 ^aDepartment of Microbiology & Immunology, University of North Carolina at Chapel Hill,
8 Chapel Hill, NC, USA

9 ^bDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC,
10 USA

11 ^cPresent address: EpiCypher, Research Triangle Park, NC, USA

12

13 *Equal contribution

14 #Corresponding author

15

16 Word count

17 Abstract: 246

18 Text: 10,656

19

20

21 **ABSTRACT**

22 Powassan virus (POWV) is an emerging tick-borne flavivirus that causes neuroinvasive
23 disease, including encephalitis, meningitis, and paralysis. Similar to other neuroinvasive
24 flaviviruses, such as West Nile virus (WNV) and Japanese encephalitis virus (JEV),
25 POWV disease presentation is heterogeneous, and the factors influencing disease
26 outcome are not fully understood. We used Collaborative Cross (CC) mice to assess the
27 impact of host genetic factors on POWV pathogenesis. We infected a panel of *Oas1b*-
28 null CC lines with POWV and observed a range of susceptibility phenotypes, indicating
29 that host factors other than the well-characterized flavivirus restriction factor *Oas1b*
30 modulate POWV pathogenesis in CC mice. Among *Oas1b*-null CC lines, we identified
31 multiple highly susceptible lines (0% survival), including CC071, and a single resistant
32 line (78% survival), CC045. Susceptibility phenotypes generally were concordant among
33 neuroinvasive flaviviruses, although we identified one line, CC006, that was resistant
34 specifically to JEV, suggesting that both pan-flavivirus and virus-specific mechanisms
35 contribute to susceptibility phenotypes in CC mice. We found that POWV replicated to
36 higher titers in bone marrow-derived macrophages from CC071 mice compared to CC045
37 mice, suggesting that resistance could result from cell-intrinsic restriction of viral
38 replication. Although serum viral loads at 2 days post-infection were equivalent between
39 CC071 and CC045 mice, clearance of POWV from the serum was significantly slower in
40 CC071 mice. Furthermore, CC045 mice had significantly lower viral loads in the brain at
41 7 days post-infection compared to CC071 mice, suggesting that reduced CNS infection
42 contributes to the resistant phenotype of CC045 mice.

43

44 **IMPORTANCE**

45 Neuroinvasive flaviviruses, such as WNV, JEV, and POWV, are transmitted to humans
46 by mosquitoes or ticks, can cause neurologic disease, such as encephalitis, meningitis,
47 and paralysis, and can result in death or long-term sequelae. Although potentially severe,
48 neuroinvasive disease is a rare outcome of flavivirus infection. The factors that determine
49 whether someone develops severe disease after flavivirus infection are not fully
50 understood, but host genetic differences in polymorphic antiviral response genes likely
51 contribute to disease outcome. We evaluated a panel of genetically diverse mice and
52 identified lines with distinct outcomes following infection with POWV. We found that
53 resistance to POWV pathogenesis corresponded to reduced viral replication in
54 macrophages, more rapid clearance of virus in peripheral tissues, and reduced viral
55 infection in the brain. These susceptible and resistant mouse lines will provide a system
56 for investigating the pathogenic mechanisms of POWV and identifying polymorphic host
57 genes that contribute to resistance.

58

59

60 INTRODUCTION

61 Neuroinvasive flaviviruses such as West Nile virus (WNV), Japanese encephalitis
62 virus (JEV), St. Louis encephalitis virus (SLEV), tick-borne encephalitis virus (TBEV), and
63 Powassan virus (POWV) are transmitted to humans by mosquitoes or ticks and can
64 spread from the circulation into the central nervous system (CNS) (1, 2). Flavivirus
65 infections exhibit a heterogenous presentation, with ~80% of infections being
66 asymptomatic and ~20% presenting with febrile symptoms. A subset of individuals with
67 symptomatic WNV, JEV, SLEV, TBEV, or POWV infection progress to severe,
68 neuroinvasive disease (e.g., encephalitis, meningitis, or paralysis), which can be fatal or
69 lead to long-term cognitive and functional sequelae. Neurologic disease can result from
70 direct viral infection of neurons and also from the inflammatory response triggered by a
71 viral infection of the CNS. However, the factors influencing susceptibility to severe
72 neuroinvasive disease remain incompletely understood.

73 POWV is an emerging tick-borne flavivirus within the tick-borne encephalitis
74 serocomplex that is transmitted by the same *Ixodes* ticks that transmit Lyme disease (3).
75 POWV is the only tick-borne flavivirus found in North America. Like other tick-borne
76 diseases, the incidence of POWV infection is increasing (4). POWV was first isolated from
77 the brain of a young boy who died of encephalitis in 1958 in Powassan, Ontario, Canada
78 (5). Forty years later, a virus sharing 94% amino acid identity with POWV was isolated
79 from a deer tick (*Ixodes scapularis*), and was named deer tick virus (DTV) (6, 7). POWV
80 circulates as two distinct but serologically indistinguishable genotypes: Lineage I
81 containing the prototype POWV, and Lineage II, containing DTV (6-8). Infection with
82 POWV can have devastating impacts, as approximately 10% of reported encephalitic

83 cases of POWV are fatal, and over 50% of survivors experience long-term cognitive and
84 functional sequelae (9).

85 Flavivirus infection in humans is characterized by significant variation in disease
86 severity, suggesting that host genetic factors impact the probability and outcome of
87 neuroinvasive disease (10-16). Host genes related to the antiviral immune response have
88 been associated with the outcome of flavivirus infection in humans (16). For example,
89 polymorphisms in the dsRNA sensor OAS1 and the chemokine receptor CCR5 are
90 associated with WNV and TBEV infection, symptomatic presentation, and neuroinvasive
91 disease (10, 14, 17, 18). Flavivirus resistance is one of the earliest examples of a genetic
92 determinant of pathogen susceptibility defined in mice. In the 1930s, resistance to
93 flavivirus disease was shown to be inherited in mice (19) and in the 2000s, resistance
94 was mapped to the 2'-5' oligoadenylate synthetase 1b (*Oas1b*) gene (20, 21). The antiviral
95 activity of *Oas1b* restricts all flaviviruses tested and appears to act exclusively against
96 flaviviruses. Genetic resistance to tick-borne flavivirus disease was demonstrated in the
97 1930s by selective breeding of mouse lines that were either resistant or susceptible to
98 TBEV and louping ill virus (22, 23) and similar studies demonstrated differential
99 susceptibility to the mosquito-borne flaviviruses St. Louis encephalitis virus and yellow
100 fever virus (24-28).

101 The Collaborative Cross (CC) is a mouse genetic reference population of
102 recombinant inbred lines. These lines were generated by crossing eight founder strains
103 that represent three wild-derived and five classical laboratory mouse lines and then
104 independently inbreeding each family deriving from one of these 8-founder funnels (29,
105 30). The CC captures the genetic diversity of laboratory mice, roughly on par with levels

106 of common human genetic variation, in a reproducible manner, since each of the 63 lines
107 has a known and fixed genome, providing a valuable tool for mapping complex traits (29-
108 33). As such, the CC enables the identification and study of polymorphic host genes
109 underlying complex phenotypes including the immune response to viral infection (29-35).
110 Further, since each line is inbred, the CC can be used to facilitate the study of phenotypes
111 that are diverse and dynamic through time (such as the response to infection) in a
112 reproducible manner.

113 Common laboratory mouse lines (including CC founder lines C57BL/6, A/J, 129,
114 NOD, and NZO) have truncated *Oas1b* alleles that lack 30% of the C terminal sequence
115 due to a premature stop codon, whereas wild-derived lines (CC founder lines WSB, PWK,
116 and CAST) each have unique full-length *Oas1b* alleles, meaning that CC lines carry either
117 a full-length or truncated allele of *Oas1b*. Previous studies using F1 hybrids of CC mice
118 to define genetic determinants of WNV pathogenesis found via genetic mapping that
119 *Oas1b* had a major impact on WNV disease outcome (36, 37). However, the mechanism
120 by which *Oas1b* restricts flavivirus infection remains unclear, since both full-length and
121 truncated *Oas1b* proteins lack synthetase activity (38, 39), although full-length *Oas1b*
122 does inhibit *Oas1a* synthetase activity and reduces 2'-5' linked oligoadenylate production
123 (38).

124 In this study, we used CC mice to investigate the effect of host genetics on disease
125 outcome following neuroinvasive flavivirus infection. We found that a panel of *Oas1b*^{null}
126 CC lines had a range of susceptibility phenotypes following POWV infection and we used
127 susceptible and resistant lines to investigate mechanisms of POWV pathogenesis. We
128 found that resistance to POWV pathogenesis corresponded to reduced viral replication in

129 macrophages, more rapid clearance of virus in peripheral tissues, and reduced viral
130 infection in the brain. These findings reveal diverse pathologic outcomes of POWV
131 infection in CC mice and suggest that rapid clearance of POWV in the periphery
132 contributes to reduced neuroinvasion and resistance to lethality. These susceptible and
133 resistant mouse lines will provide a system for investigating the pathogenic mechanisms
134 of POWV and identifying polymorphic host genes that contribute to resistance.

135

136 **RESULTS**

137

138 ***Oas1b* restricts pathogenesis of neuroinvasive flaviviruses.** To assess the effect of
139 *Oas1b* on neuroinvasive flavivirus pathogenesis in CC mice, we infected three strains of
140 mice: wild-type C57BL/6J (non-functional *Oas1b* allele); CC019 (functional *Oas1b* allele
141 derived from the WSB founder strain), and an *Oas1b*^{del} line on a CC019 background
142 generated by CRISPR/Cas-9 gene editing (see Methods). We infected 5-6-week-old mice
143 with 100 FFU of POWV (strains LB or DTV Spooner), WNV, or JEV and monitored
144 survival for 21 days (Fig. 1A-D). As expected, CC019 mice were resistant to all three
145 viruses, consistent with a strong effect of *Oas1b* on susceptibility to neuroinvasive
146 flaviviruses. We found that CC019-*Oas1b*^{del} mice were susceptible to POWV LB, POWV
147 DTV, WNV, and JEV (80%, 73%, 75% and 60% lethality, respectively). To determine
148 whether genetic determinants of susceptibility in mice corresponded to differences in viral
149 replication, we performed multi-step growth curves in primary mouse embryo fibroblasts
150 (MEFs). We generated MEFs from C57BL/6J, CC019, and CC019-*Oas1b*^{del} mice,
151 infected with POWV or WNV at an MOI of 0.1, and measured viral titers in the culture




Figure 1. Oas1b restricts pathogenesis of diverse neuroinvasive flaviviruses. A-D. Five to six-week-old male and female CC019, CC019-Oas1b^{del}, or C57BL/6J mice were infected with 100 FFU of POWV strain LB (A), POWV DTV strain DTV (B), WNV strain NY2000 (C), or JEV strain Nakayama (D) by subcutaneous inoculation in the footpad and lethality was monitored for 21 days. Data are combined from 4-5 experiments per virus. E-F. Mouse embryo fibroblasts (MEFs) were harvested from the indicated mouse lines for multistep growth curve analysis. MEFs were infected at an MOI of 0.01 with POWV strain LB (E) or WNV strain NY2000 (F). Supernatants were collected at 4, 24, 48, or 72 hours post-infection and titrated by focus-forming assay on Vero cells. Results shown are the mean +/- SEM of 2-3 independent experiments performed in duplicate or triplicate. Asterisks represent statistical significance (* p<0.05, ** p<0.01, *** p<0.001) by two-way ANOVA compared to CC019-Oas1b^{del}. G-H. Nine to twelve-week-old C57BL/6J wild-type or Oas1g^{-/-} male and female mice were infected with 100 FFU of POWV strain MB5/12 (G) or WNV strain NY2000 (H) by subcutaneous inoculation in the footpad and lethality was monitored for 21 days.

152 supernatant over 72 hrs (Fig. 1E-F). POWV replication was significantly higher in MEFs
 153 derived from C57BL/6J mice compared to CC019-Oas1b^{del} mice starting at 24 hpi (Fig.
 154 1E), with a maximum difference of 8-fold at 48 hpi; WNV-infected MEFs were only
 155 significantly different at 72 hpi (4-fold) (Fig. 1F). POWV and WNV replication in CC019-
 156 Oas1b^{del} MEFs were only modestly increased compared to CC019 MEFs (2- and 3-fold,
 157 respectively), and only at 48 hpi. Altogether these results suggest that non-Oas1b genetic
 158 factors are responsible for the differences in viral replication in MEFs.

159 Humans have four paralogous OAS genes: *OAS1*, *OAS2*, *OAS3*, and *OASL*. Mice,
160 however, have single copies of *Oas2* and *Oas3*, two copies of *OasL*, and eight copies of
161 *Oas1* (*Oas1a*-*Oas1h*) (39). To determine whether other *Oas1* paralogs play a similar role
162 in restricting flavivirus pathogenesis as *Oas1b*, we infected 9 to 12-week-old *Oas1g*^{-/-}
163 mice (C57BL/6N background) or wild-type mice (C57BL/6J background) with POWV
164 strain MB5/12 or WNV and monitored lethality for 21 days. These older mice were more
165 resistant to POWV and WNV pathogenesis compared to the 5- to 6-week-old mice used
166 in the previous experiments, but we found no significant difference in survival for *Oas1g*
167 ^{-/-} mice compared to wild-type (Fig. 1G-H), suggesting the function of *Oas1b* as a flavivirus
168 restriction factor is not conserved among all *Oas1* paralogs.

169

170 ***Oas1b*-null Collaborative Cross lines exhibit a range of susceptibility phenotypes**
171 **to neuroinvasive flaviviruses.** To investigate the role of host genetic factors outside of
172 the well-known flavivirus restriction factor *Oas1b*, we infected mice from a panel of 16 CC
173 strains (9 to 12-week-old mice, all lines possessing *Oas1b*^{null} alleles), as well as CC019-
174 *Oas1b*^{del} mice, with POWV
175 strain LB and monitored
176 lethality for 21 days (Fig. 2
177 and Table 1). As expected,
178 most lines were highly
179 susceptible to POWV (100%
180 lethality in 11 of 17 CC lines).
181 However, we identified one




Figure 2. Host factors influence POWV pathogenesis across *Oas1b*-null Collaborative Cross mouse lines. Nine to twelve-week-old male and female mice were infected with 100 FFU of POWV (strain LB) by subcutaneous inoculation in the footpad and lethality was monitored for 21 days. Lines are ordered by percent survival and mean time to death. N=34 C67BL/6 mice, 18 CC019-*Oas1b*^{del} mice, and 6-7 mice for other lines. Data are combined from 9 experiments.

182 resistant line (CC045, 0% lethality), and five lines with intermediate susceptibility (CC001,
 183 CC027, CC043, CC057, CC062, 50-83% lethality).

184 To validate the phenotypes observed with POWV strain LB, we infected a subset
 185 of the *Oas1b*^{null} CC lines with POWV strain MB5/12, WNV strain NY2000, JEV strain
 186 Nakayama, or St. Louis encephalitis virus (SLEV) strain GHA-3 and monitored lethality
 187 for 21 days (Fig. 3A-D). CC071 mice were highly susceptible to all viruses tested, with
 188 100% lethality observed after infection with POWV MB5/12 (Fig. 3A) or WNV (Fig. 3B),
 189 91% lethality in JEV-infected mice (Fig. 3C). CC071 mice exhibited 57% lethality after
 190 SLEV infection, which was remarkable as C57BL/6J and CC019-*Oas1b*^{del} mice exhibited
 191 no lethality after SLEV infection (Fig. 3D). Furthermore, CC045 mice, which were the most
 192 resistant CC line to POWV LB (100% survival, Fig. 2), also were relatively resistant to
 193 POWV MB5/12 (78% survival, Fig. 3A), WNV (50% survival, Fig. 3B), and JEV (50%




Figure 3. Susceptibility phenotypes in Collaborative Cross mice are shared among diverse neuroinvasive flaviviruses. A-D. Nine to twelve-week-old male and female mice from *Oas1b*-null CC lines were infected with 100 FFU of POWV strain MB5/12 (A), WNV strain NY2000 (B), JEV strain Nakayama (C), or SLEV strain GHA-3 (D) by subcutaneous inoculation in the footpad and lethality was monitored for 21 days. Data are combined from 4-8 experiments per virus. E. Nine to twelve-week-old male mice from *Oas1b*^{+/+} CC lines were infected with 100 FFU of POWV strain MB5/12 and lethality was monitored for 21 days. Data represent a single experiment.

194 survival, Fig. 3C). Thus, most susceptibility phenotypes were concordant among POWV,
195 WNV, and JEV. However, some lines exhibited virus-specific susceptibility. CC006 mice
196 were highly susceptible to WNV (100% lethality, Fig. 3B), intermediately susceptible to
197 POWV MB5/12 (56% lethality, Fig. 3A), yet were the most resistant CC line to JEV (37%
198 lethality, Fig. 3C). This suggests that there are both pan-flavivirus and virus-specific
199 mechanisms that control susceptibility to neuroinvasive flaviviruses. We also evaluated
200 CC lines with functional *Oas1b* alleles (CC003, WSB allele; CC004, PWK allele; and
201 CC030, WSB allele). As expected, these mice were resistant to POWV MB5/12 infection
202 (0% lethality, Fig. 3E), further supporting that functional *Oas1b* alleles derived from
203 different CC founder lines restrict neuroinvasive flavivirus pathogenesis in CC mice.

204

205 **Susceptibility of Collaborative Cross lines to neuroinvasive flavivirus**
206 **pathogenesis does not correlate with early viremia levels.** To uncover the pathogenic
207 mechanisms behind the differences in flavivirus susceptibility among *Oas1b*^{null} CC lines,
208 we investigated whether resistance to lethality corresponded with decreased viremia. We
209 measured viral loads in the serum by quantitative reverse transcription-PCR (qRT-PCR)
210 in serum collected 2 dpi from *Oas1b*^{null} CC lines (CC045, CC057, CC006, CC019-*Oas1b*
211 ^{+/−}, CC015, and CC071) infected with POWV, WNV, or JEV (Fig. 4). Surprisingly, we found
212 no concordance between mean viremia (Fig. 4A, C, D) and susceptibility (Fig. 3A-C)
213 among the *Oas1b*^{null} CC lines tested. Furthermore, viral loads in the serum were similar
214 between *Oas1b*^{null} CC mice (Fig. 4A) and *Oas1b*^{+/+} CC mice (Fig. 4B). Moreover, within
215 CC lines, there was no difference in viremia between mice that survived (open symbols)
216 compared to mice that succumbed to infection (closed symbols). These data suggest that




Figure 4. Serum viral loads at 2 dpi do not correlate with susceptibility to neuroinvasive flaviviruses. Nine to twelve-week-old male and female mice were infected with 100 FFU of POWV (A and B), WNV (C), or JEV (D) by subcutaneous inoculation in the footpad. Mice were bled 2 dpi and viremia was assessed by qRT-PCR. Asterisks represent statistical significance (* $p < 0.05$, *** $p < 0.001$) by one-way ANOVA compared to CC045 (panels A, C, and D). CC lines in A, C, and D are all Oas1b-null; CC lines in B are Oas1b^{+/+}. Open symbols denote surviving mice.

217 controlling viremia at 2 dpi is not the mechanism of resistance to flavivirus pathogenesis

218 in these CC lines.

219

220 **Resistance to neuroinvasive flavivirus pathogenesis correlates with reduced**


221 **replication in macrophages.** To evaluate whether resistance to POWV disease

222 corresponds with cell-intrinsic restriction of viral replication, we generated bone marrow-

223 derived macrophages (BMDM) from CC mice and performed multi-step growth curves

224 with POWV and WNV (Fig. 5). BMDMs from CC071 and CC015 mice produced

225 significantly
226 higher viral titers
227 of POWV
228 compared to
229 BMDMs from



230 CC045 mice Figure 5. Susceptibility to flavivirus disease is concordant with restriction of viral
231 (417-fold and replication in macrophages ex vivo. Bone marrow-derived macrophages (BMDM)
232 24-fold higher at were harvested from CC mice (CC045, CC071, and CC015) for multistep growth curve
233 72 hpi) (Fig. 5A), analysis. BMDMs were infected at an MOI of 0.01 with POWV (A) or WNV (B). Super-
234 concordant with the increased susceptibility of CC071 and CC015 mice to POWV
235 infection (Fig. 3A). Similarly, BMDMs from CC015 mice exhibited enhanced WNV
236 replication at 24 and 48 hpi, and CC071-derived BMDMs had significantly higher viral
237 titers at 24 hpi, compared to BMDMs from CC045 mice (18-fold and 9-fold higher at 24
238 hpi) (Fig. 5B). Thus, resistance to flavivirus disease in CC mice could result from cell-
239 intrinsic restriction of viral replication in macrophages, a key cellular target of flaviviruses
240 *in vivo*.

241

242 **Resistance to POWV pathogenesis correlates with rapid clearance of peripheral**
243 **infection and lower CNS viral loads.** Although we found no difference in serum viral
244 loads at 2 dpi between susceptible and resistant CC lines (Fig. 4), susceptibility to
245 neuroinvasive flaviviruses could be driven by serum viral loads at later time points, or by
246 viral loads in the CNS, independent of viremia. To further investigate the pathogenic
247 mechanisms of POWV infection, we infected CC lines identified as susceptible (CC071)

248 and resistant (CC045) and measured viral loads in serum, spleen, and brain at 3 and 7
249 dpi. CC071 mice exhibited high viremia at 3 dpi (mean $7.9 \log_{10}$ copies/ml of serum) and
250 POWV RNA was detected in the serum of all 8 CC071 mice harvested at 7 dpi (Fig. 6A).
251 However, 2 of 5 CC045 mice had cleared POWV from the serum by 3 dpi, and viremia
252 was low in the remaining CC045 mice (maximum $5.7 \log_{10}$ copies/ml of serum), and




Figure 6. Reduced CNS viral loads correlate with POWV resistance. Nine to twelve-week-old male and female CC071 (susceptible) and CC045 (resistant) mice were infected with 100 FFU of POWV (strain MB5/12) by subcutaneous inoculation in the footpad. A-D. At the indicated time points, mice were perfused and tissues were harvested. A. Mice were bled by cardiac puncture prior to perfusion and viremia was assessed by qRT-PCR. B-D. Spleen, brain, and spinal cord homogenates were titrated by plaque assay on Vero cells. E-F. Mice were serially bled 2, 3, and 4 dpi and viremia was assessed by qRT-PCR. Asterisks represent statistical significance (* $p < 0.05$, *** $p < 0.001$) by two-way ANOVA.

253 POWV RNA was not detected in the serum of any of the 5 CC045 mice harvested at 7
254 dpi (Fig. 6A). This suggests that while viral loads in the serum at 2 dpi were equivalent
255 between susceptible (CC071) and resistant (CC045) lines (Fig. 4A), clearance of POWV
256 from the serum was faster in CC045 mice. Despite a >350-fold difference in serum viral
257 loads at 3 dpi between CC071 and CC045 mice, we found no significant difference in
258 spleen viral loads at 3 dpi (Fig. 6B). In contrast, by 7 dpi, all CC045 mice had cleared
259 POWV from the spleen, while CC071 mice had viral loads in the spleen similar to those
260 observed at 3 dpi (Fig. 6B), concordant with the sustained viremia in CC071 mice through
261 7 dpi (Fig. 6A). We also assessed viral loads in the CNS and found that POWV was
262 undetectable in the brains of CC071 and CC045 mice at 3 dpi, but by 7 dpi, all CC071
263 mice had high viral loads in the brain (mean $6.3 \text{ Log}_{10} \text{ PFU/ml}$) (Fig. 6C). Interestingly,
264 while 4 of 6 CC045 mice had undetectable viral loads in the brain at 7 dpi, the remaining
265 2 mice had brain viral loads similar to CC071 mice (maximum $6.3 \text{ log}_{10} \text{ PFU/ml}$) (Fig. 6C).
266 The observation that 33% of CC045 mice had detectable virus in the brain at 7 dpi (Fig.
267 6C) is concordant with our earlier observation that CC045 mice had 22% lethality to
268 POWV strain MB5/12 (Fig. 3A). POWV was undetectable in the spinal cords of CC071
269 mice at 3 dpi, but by 7 dpi, 2 of 9 CC071 mice had high viral loads in the spinal cord
270 (maximum $7.8 \text{ log}_{10} \text{ PFU/ml}$) (Fig. 6D). Interestingly, the 2 CC071 mice that had high viral
271 loads in the spinal cord also had the highest viral loads in the brain at 7 dpi, suggesting
272 the presence of POWV in the spinal cord is due to viral spread within the CNS rather than
273 separate stochastic breaches of the blood-brain barrier (BBB). Further, POWV was not
274 detected in spinal cords from CC045 mice at 3 or 7 dpi (Fig. 6D). Altogether, these data

275 suggest the mechanism of resistance to POWV infection in CC045 mice is the prevention
276 of neuroinvasion.

277 To further investigate differences in the rate of clearance of POWV from the
278 periphery in susceptible and resistant mice, we infected CC071 and CC045 mice and
279 performed serial measurements of viral loads in the serum at 2, 3, and 4 dpi to analyze
280 the kinetics of viremia in individual mice. Consistent with our previous experiments, we
281 found that CC071 mice had high viral loads at 2 dpi (mean $6.5 \log_{10}$ copies/ml), which
282 peaked at 3 dpi (mean $7.5 \log_{10}$ copies/ml), and remained high in 7 of 8 mice at 4 dpi
283 (mean $6.5 \log_{10}$ copies/ml) (Fig. 6D). While CC045 mice had high viral loads in the serum
284 at 2 dpi (mean $5.7 \log_{10}$ copies/ml), 6 of 8 mice had undetectable viremia at 3 dpi, and
285 all mice had cleared by 4 dpi (Fig. 6E). The viremia kinetics observed in individual CC045
286 and CC071 mice (Fig. 6D-E) are concordant with our earlier observation in terminally-
287 bled mice that CC045 mice clear POWV from the periphery more rapidly than CC071
288 mice (Fig. 6A). Altogether, these data support a model of POWV pathogenesis in which
289 rapid clearance of viremia reduces the likelihood of virus breaching the BBB and
290 accessing the CNS, where viral infection results in mortality.

291

292 **DISCUSSION**

293 In this study, we investigated the effect of host genetics on disease outcome
294 following neuroinvasive flavivirus infection. We found that a panel of *Oas1b*^{null} CC lines
295 had a range of susceptibility phenotypes following POWV infection, indicating that
296 polymorphic host genes other than *Oas1b* contribute to disease outcome after POWV
297 infection. We identified *Oas1b*^{null} CC lines that are susceptible (100% lethality) or resistant

298 (<25% lethality) to POWV and used these lines to investigate mechanisms of POWV
299 pathogenesis. We observed reduced POWV and WNV replication in primary
300 macrophages derived from resistant mice, suggesting resistance to flavivirus disease in
301 CC mice could result from cell-intrinsic restriction of viral replication in macrophages. We
302 found no differences in POWV viremia between susceptible and resistant CC mice at 2
303 dpi but found that resistant mice cleared POWV from the periphery rapidly whereas
304 susceptible mice had high viremia throughout the infection. Further, we observed
305 significant differences in viral loads in the brains of susceptible and resistant CC mice
306 following POWV infection. These findings reveal diverse pathologic outcomes of POWV
307 infection in CC mice and suggest that rapid clearance of POWV in the periphery
308 contributes to reduced neuroinvasion and protection from lethality.

309 Neuroinvasive flaviviruses, such as WNV, JEV, and POWV, can cause neurologic
310 disease, such as encephalitis, meningitis, and paralysis, and can result in death or long-
311 term cognitive and functional sequelae (1, 2, 40). JEV is the most prevalent cause of viral
312 encephalitis worldwide, causing an estimated 68,000 cases and >10,000 deaths annually
313 throughout east and southeast Asia, even though a vaccine is available (41, 42). In 2022,
314 local transmission of JEV was detected in Australia for the first time since 1995 and
315 ultimately led to dozens of reported JEV cases within Australia (43). In North America,
316 West Nile virus (WNV) is the most common cause of viral encephalitis, with 1,855 cases
317 of West Nile neuroinvasive disease reported to the CDC in 2021 and a total of 25,849 US
318 cases since 1999 when the virus was introduced to North America (44). While JEV and
319 WNV are transmitted to humans by mosquitoes, TBEV and POWV are transmitted by
320 ticks. TBEV causes >10,000 cases of encephalitis annually in Europe and Asia despite

321 the availability of a vaccine (45, 46). POWV is the only tick-borne flavivirus found in North
322 America and like other tick-borne diseases, the incidence of POWV infection is increasing
323 (4). Given the clinical importance of endemic neuroinvasive flaviviruses, as well as the
324 potential for related flaviviruses such as Usutu virus (USUV) to emerge as new human
325 pathogens (47, 48), it is important to understand the factors that lead to severe clinical
326 outcomes after infection with these viruses.

327 Neurotropic viruses, including neuroinvasive flaviviruses, can cause disease by
328 direct damage to infected neurons, as well as by stimulating pathogenic inflammatory
329 responses (49-52). The pathogenic mechanisms of neuroinvasive flaviviruses have been
330 studied extensively in mice, which recapitulate key features of human disease such as
331 neuronal infection, immune infiltration into the CNS, paralysis, encephalitis, and cognitive
332 loss. Much of this work has focused on WNV, but more recent studies have investigated
333 POWV pathogenesis in mice; these studies have studied POWV disease using laboratory
334 mouse lines such as C57BL/6J and Balb/c, as well as *Peromyscus* mice which are
335 thought to serve as reservoirs for Lineage II POWV (DTV) in nature (53-57). C57BL/6J
336 mice are highly susceptible to POWV, which makes them useful for modeling severe
337 human disease, but makes them less useful for defining the mechanisms that allow the
338 majority of infected individuals to sustain mild or asymptomatic infections while a small
339 subset of infected individuals develop severe neuroinvasive disease. Comparing POWV
340 infection in resistant CC lines (e.g., CC045) to susceptible lines (e.g., CC071) has the
341 potential to reveal which aspects of POWV infection and the resulting host immune
342 response (e.g., viral loads in the periphery, persistent viremia, neuroinvasion, replication
343 within the CNS, damage to CNS neurons, neuroinflammation, etc.) correlate with severe

344 neurologic disease. CC mice can be useful models of relevant disease presentations that
345 are not evident in conventional laboratory mouse lines, such as encephalitis caused by
346 Rift Valley fever virus (34) or chronic WNV disease (58).

347 Altogether, our results support a model in which CC045 mice are resistant to
348 severe POWV disease due to reduced viral replication in myeloid cells and rapid
349 clearance of viremia, reducing the probability of neuroinvasion, and that this resistance is
350 independent of a role for Oas1b in restricting flavivirus pathogenesis. This model
351 suggests that the resistance mechanism of CC045 mice acts in peripheral tissues, not
352 within the CNS. Although the mechanisms by which flaviviruses cross the blood-brain
353 barrier and invade the CNS remain incompletely understood (59), hematogenous
354 neuroinvasion likely is somewhat stochastic and prolonged high viremia (e.g., in CC071
355 mice) increases the probability of virus crossing the BBB. We expect that once any POWV
356 accesses the CNS it encounters a highly permissive and sensitive environment, resulting
357 in uniform lethality. Accordingly, while we detected no virus in the brains of most CC045
358 mice, 2 of 6 CC045 mice did have virus in their brains and at levels equivalent to CC071
359 mice, consistent with the ~22% lethality we observed for CC045 mice. The model that
360 CC045 resistance results from rapid clearance of viremia is somewhat at odds with the
361 observation that susceptibility did not correlate with 2 dpi viremia either within or among
362 CC lines. However, this model is supported by the distinct viremia kinetics between
363 CC045 and CC071 mice and suggests that rapid clearance, but not peak viremia, is a key
364 determinant of POWV susceptibility in CC mice. Future studies will characterize viral
365 replication in cell types other than macrophages and will compare CNS immune infiltrates

366 and CNS pathology in CC045 mice versus CC071 to determine whether these lines differ
367 in BBB permeability at baseline and in response to POWV infection.

368 In general, the susceptibility phenotypes we observed were concordant among the
369 neuroinvasive viruses tested, suggesting that CC045 resistance likely results from a pan-
370 flavivirus mechanism. However, we found that CC006 mice were highly susceptible to
371 WNV and POWV but relatively resistant to JEV. Future studies will investigate the
372 mechanism of JEV resistance in CC006 mice, potentially revealing disease mechanisms
373 that are specific to JEV compared to other flaviviruses.

374 Host genes related to the antiviral immune response have been associated with
375 the outcome of flavivirus infection in humans (16). For example, a common polymorphism
376 that ablates expression of the chemokine receptor CCR5 (CCR5 Δ 32, best characterized
377 because homozygotes are protected against HIV infection because CCR5 is the main co-
378 receptor for HIV entry (60)) is associated with higher risk of WNV and TBEV symptomatic
379 presentation and neuroinvasive disease (10, 14, 17, 18). A protective role for CCR5
380 against WNV and TBEV disease is consistent with studies showing that CCR5 deficient
381 mice exhibit impaired trafficking of CD8 T cells necessary to clear flavivirus CNS infection
382 (61-64). Furthermore, polymorphisms in the dsRNA sensors OAS1, OAS2, and OAS3 are
383 associated with WNV and TBEV infection and neuroinvasive disease (10, 65, 66).
384 Mechanistically, the SNP rs10774671 of OAS1 corresponds to a A>G change in a splice
385 acceptor site, where the G allele (protective) generates the p46 isoform of OAS1. The
386 p46 isoform is prenylated, localizes to flavivirus replication complexes on ER membranes,
387 and inhibits WNV replication, whereas the p42 isoform (resulting from the A allele) is not
388 prenylated and lacks antiviral activity (67). Among the 8 murine orthologs of OAS1, Oas1b

389 and Oas1g both encode a C-terminal CaaX domain homologous to the prenylation site in
390 the p46 isoform of human OAS1 (67). But whereas Oas1b plays a dominant role
391 restricting flavivirus pathogenesis in mice, we found no effect of Oas1g on survival after
392 WNV or POWV infection. This could indicate that Oas1g is not important for controlling
393 flavivirus infection, that the antiviral effects of Oas1g are not strong enough to affect
394 lethality, or that the antiviral effects of Oas1g are not evident on the *Oas1b*^{null} C57BL/6J
395 genetic background.

396 Polymorphisms within additional antiviral response genes (e.g., CD209/DC-SIGN,
397 TLR3, IL-10) are associated with TBEV infection (11-15). Similarly, polymorphisms within
398 antiviral response genes such as HERC5, IRF3, and MX1 are associated with WNV
399 infection (10, 16, 68, 69). Other polymorphic host genes play a role in flavivirus infection,
400 although their effect on human disease is less clear. TMEM41B is an ER-associated lipid
401 scramblase that promotes replication of a wide variety of flaviviruses (including POWV,
402 TBEV, and WNV) (70). TMEM41B is polymorphic in humans and TMEM41B alleles vary
403 in their ability to support flavivirus replication in cell culture (70), although associations
404 with the risk or outcome of flavivirus infection remain to be demonstrated.

405 Extensive studies using transgenic knockout mice have revealed the effects of
406 various innate and adaptive immune genes on the pathogenesis of WNV and other
407 flaviviruses (71) but investigating flavivirus pathogenesis in CC mice allows us to study
408 complex traits and polymorphic alleles that better recapitulate the genetic diversity found
409 in human populations (30, 33). A limitation of CC studies is that they can only reveal
410 genetic factors that are polymorphic among the 8 CC founder lines (or private mutations
411 that arose during the breeding of CC lines). Future studies will use F2 crosses of resistant

412 (e.g., CC045) and susceptible (e.g., CC071) CC lines and genetic mapping approaches
413 to define the host genetic factors that contribute to the resistant phenotype of CC045
414 mice, analogous to previous studies that have used similar approaches to map QTL and
415 underlying causal genes that contribute to host control of influenza A virus, SARS-CoV,
416 SARS-CoV-2, and WNV (35, 37, 72-74).

417 Previous studies have used CC mice to investigate host genetic factors controlling
418 WNV infection and pathogenesis (36, 37, 58, 75-77). These studies used F1 crosses of
419 CC parental lines, so it is not straightforward to draw comparisons with the phenotypes
420 we identified in CC parental lines. Further, our key lines of interest, CC045 and CC071,
421 were not included in the earlier WNV studies. However, the QTL with the largest effect
422 size identified in these studies mapped to *Oas1b* (36, 37). With this in mind, we designed
423 our experiments to use only *Oas1b*^{null} CC lines, allowing us to identify other polymorphic
424 genes that contribute to disease outcome. However, our design does not detect factors
425 that are dependent upon or synergize with *Oas1b* for their activity. Since we expected
426 *Oas1b*^{null} mice to be susceptible to neuroinvasive flaviviruses, the remarkable finding in
427 our study was that CC045 mice were resistant to diverse neuroinvasive flaviviruses, even
428 in the absence of *Oas1b*. We also identified other *Oas1b*^{null} CC lines (such as CC057)
429 with more modest resistance phenotypes; future studies will investigate whether the
430 resistant phenotype of CC057 mice derives from the same mechanism as CC045 mice.
431 Notably, CC057 mice also were relatively resistant to RVFV, exhibiting a delayed disease
432 course resulting in encephalitis rather than acute hepatitis (34). CC071 mice, which we
433 identified as being highly susceptible to POWV, WNV, JEV, and SLEV previously have
434 been found to be highly susceptible to SARS-CoV-2 (78) and RVFV (34) and were highly

435 susceptible to ZIKV when treated with an IFNAR1-blocking antibody (79). Altogether this
436 suggests that CC mice can reveal immune mechanisms that control pathogenesis of
437 diverse viruses.

438 In this study, we demonstrated that *Oas1b* restricts POWV pathogenesis, which
439 was not surprising given that *Oas1b* has been shown to restrict all flaviviruses tested to
440 date. Despite observing marked differences in survival between CC019-*Oas1b*^{del} and
441 CC019 mice, we found no significant difference in WNV or POWV replication in CC019-
442 *Oas1b*^{del} MEFs compared to CC019 MEFs, even though *Oas1b* has been shown to
443 restrict flavivirus replication in MEFs derived from C3H.PRI-Flv^r mice (80). This
444 discordance could be due to distinct genetic features of CC019 mice and differences
445 between MEFs and other cell types. In this study, we also demonstrated the ability to
446 generate genetic knockouts on a CC background (CC019-*Oas1b*^{del}), which will enable
447 the study of the function of single genes in the context of genetically diverse mouse
448 models.

449 Prevention of neuroinvasion could be achieved by one or more mechanisms,
450 including a tighter BBB, modulated leukocyte trafficking into the CNS, and enhanced
451 clearance of virus from the periphery. The data from the present study support a model
452 of POWV pathogenesis in which persistent high levels of viremia increases the likelihood
453 of virus stochastically breaching the BBB and accessing the CNS, where it leads to
454 mortality. Thus, we propose that CC045 mice resist POWV infection by promoting the
455 rapid clearance of POWV from the circulation and therefore limiting the opportunity for
456 POWV neuroinvasion, and this effect is mediated by host factors outside of *Oas1b*. Future
457 studies will investigate these non-*Oas1b* host factors using an F2 cross of susceptible

458 and resistant CC mice and use quantitative genetics approaches to identify polymorphic
459 genes that contribute to the resistant phenotype of CC045 mice.

460

461 MATERIALS AND METHODS

462

463 **Cells and viruses.** Vero (African green monkey kidney epithelial) cells were maintained
464 in Dulbecco's modified Eagle medium (DMEM) containing 5% heat-inactivated FBS at
465 37°C with 5% CO₂. POWV strains LB (Lineage I) and Spooner (DTV, Lineage II), WNV
466 strain NY2000, JEV strain Nakayama, and SLEV strain GHA-3 were provided by Dr.
467 Michael Diamond (Washington University in St. Louis). POWV strain MB5/12 (DTV,
468 Lineage II) was provided by Dr. Greg Ebel (Colorado State University). All viruses were
469 handled under BSL3 containment. Virus stocks were grown in Vero cells and titered by
470 focus-forming assay (FFA) (81). Duplicates of serial 10-fold dilutions of virus in growth
471 medium (DMEM containing 2% FBS and 20 mM HEPES) were applied to Vero cells in
472 96-well plates and incubated at 37°C with 5% CO₂. After 1 hour, cells were overlaid with
473 1% methylcellulose in minimum essential medium Eagle (MEM) containing 2% heat-
474 inactivated fetal bovine serum (FBS). Following incubation for approximately 24 hours
475 (WNV), 24-36 hours (JEV), or 48 hours (POWV and SLEV), plates were fixed with 2%
476 paraformaldehyde for 2 hours at room temperature. Fixed plates were incubated with 500
477 ng/ml flavivirus cross-reactive mouse MAb ZV13 (82) or E60 (83) for 2 hr at room
478 temperature or overnight at 4°C. After incubation at room temperature for 1 hr with a
479 1:2,500 dilution of horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG

480 (Sigma), foci were detected by addition of TrueBlue substrate (KPL). Foci were quantified
481 with a CTL Immunospot instrument.

482

483 **Mice.** All mouse procedures were performed under protocols approved by the Institutional
484 Animal Care and Use Committee at the University of North Carolina at Chapel Hill. CC
485 mice were obtained from the UNC Systems Genetics Core Facility directly or as breeder
486 pairs that were mated in-house. C57BL/6J mice were bred in-house. *Oas1g*^{-/-} mice were
487 obtained from Dr. Timothy Sheahan (UNC). All mouse work was performed under ABSL3
488 containment. Five-week-old or 9 to 12-week-old mice male and female mice were
489 inoculated in a volume of 50 μ l by a subcutaneous (footpad) route. Mice received 100
490 FFU of POWV strain LB, MB5/12, or Spooer (DTV), WNV strain NY2000, JEV strain
491 Nakayama or SLEV strain GHA-3, diluted in HBSS with Ca²⁺ and Mg²⁺ supplemented
492 with 1% heat-inactivated FBS. Mice were monitored daily for disease signs for 21 days or
493 until the time of tissue harvest. Mice were euthanized upon reaching humane endpoints
494 including loss of $\geq 20\%$ of starting weight, non-responsiveness, or severe neurological
495 disease signs (hunching, paralysis) interfering with the ability to access food and water;
496 euthanized mice were scored as dead the following day. To evaluate viremia, blood was
497 collected 2 dpi by submandibular bleed with a 5mm Goldenrod lancet, or by cardiac
498 puncture prior to perfusion in tissue harvest experiments.

499

500 **Generation of CC019-*Oas1b*^{del} mice.** CC019-*Oas1b*^{del} mice were generated through the
501 UNC Mutant Mouse Resource and Research Center, as part of a project to demonstrate
502 the feasibility of performing CRISPR/Cas9 genome editing in CC mice. The CC019 line

503 was chosen because it contains a functional *Oas1b* allele (derived from the WSB founder)
504 and exhibited robust superovulation and in vitro fertilization (IVF) performance, with egg
505 yields and embryo progression to the two-cell stage comparable to C57BL/6J mice. 4
506 CRISPR guide RNAs targeting the SNP position of the WSB allele were designed and
507 validated. Two guide RNAs showed full activity *in vitro* and were chosen for
508 microinjection. A donor oligonucleotide was designed to introduce the susceptible SNP
509 plus additional silent mutations to disrupt Cas9 binding and cleavage of the introduced
510 allele and to facilitate genotyping of the resulting animals. Microinjection conditions: Cas9
511 mRNA (20 or 40 ng/μl), 1 guide RNA (10 or 20 ng/μl) and donor oligonucleotide (20 or 50
512 ng/μl) were co-injected into the pronucleus of one-cell embryos produced by IVF.
513 IVF/microinjection was performed for 3 days. The CC019 strain responded moderately to
514 superovulation (average 8.3 eggs/female). IVF was successful on each of the 3 days,
515 yielding a total of 358 injectable embryos (6.2/female). Injection survival and progression
516 to the two-cell stage in vitro were comparable to C57BL/6J. However, production of live
517 pups from injected embryos was low: only 2 live pups were produced from 280 implanted
518 embryos. Both pups had CRISPR-induced mutations at the *Oas1b* locus. CC019-
519 *Oas1b*^{del} mice are homozygous for a 12 base pair deletion in exon 4 of *Oas1b* which
520 generates an in-frame 4 amino acid deletion. CC019-*Oas1b*^{del} mice were bred as
521 knockout x knockout and exhibited similar breeding performance as the parental CC019
522 line. CC019-*Oas1b*^{del} mice were genotyped by generating a PCR amplicon from tail snip
523 DNA using forward primer CCACACACAACCACCAGGAACC and reverse primer
524 GGCTGTAGGACCTCATGTCAATCA, then sequencing with the forward primer
525 TCTCATTGCCTTCTCTTCAGTGTA. The wild-type sequence is

526 GGGAGTATGGGAGTCCGAGTAACTAAATTCAACACAGCCCAGGGCTCCGAACCG
527 TCTTGGAACTGGTCACCAAGTACAAACAGCTCGAATCTACTGGACAGTGTATTAT
528 GACTTCGACATCAAGAGGTCTCTGAATACCTGCACCAA and the *Oas1b*^{del} sequence
529 is
530 GGGAGTATGGGAGTCCGAGTAACTAAATTCAACACAGCCCAGGACTTGGAACTGG
531 TCACCAAGTACAAACAGCTCGAATCTACTGGACAGTGTATTATGACTTCGACATC
532 AAGAGGTCTCTGAATACCTGCACCAA.

533

534 **Mouse Embryo Fibroblasts.** Mouse embryo fibroblasts (MEFs) were prepared from E15
535 embryos. Pregnant mice were euthanized and the gravid uterus was isolated. Embryos
536 were removed, placed in PBS, decapitated, and gut and liver were removed. Embryos
537 were then minced with scalpels, trypsinized (1 ml per embryo), pipetted up and down with
538 a 10 ml serological pipette to break up any chunks, and incubated for 5-10 min at room
539 temperature. Cells were resuspended in DMEM supplemented with non-essential amino
540 acids, L-Glutamine, Pen/Strep, and 10% heat-inactivated FBS and then pelleted by
541 centrifugation at 1000 rpm for 5 min at 4°C. Supernatants were removed and cell pellets
542 were resuspended in fresh media and pelleted again by centrifugation at 1000 rpm for 5
543 min at 4°C. Cell pellets were resuspended in 1 ml per embryo of fresh media and plated
544 into culture flasks (1.5 embryos per T-150 flask) in 25 ml of fresh media and incubated at
545 37°C with 5% CO₂. After 24 hours, media was removed, cells were washed with 1X PBS,
546 and fresh media was added. When monolayers reached near-confluence, MEFs were
547 frozen down in DMEM supplemented with non-essential amino acids, L-Glutamine,
548 Pen/Strep, 30% heat-inactivated FBS, and 20% DMSO and stored in liquid nitrogen.

549 Thawed MEFs were seeded in 6-well plates at 2×10^5 cells per well in DMEM
550 supplemented with non-essential amino acids, L-Glutamine, Pen/Strep, and 10% heat-
551 inactivated FBS. MEFs were infected at an MOI of 0.01 with POWV strain LB or WNV
552 strain NY2000. After 1 hour, inoculum was removed and replaced with fresh media and
553 plates were incubated at 37°C with 5% CO₂. After 4, 24, 48, or 72 hours, supernatants
554 were collected and titered by focus-forming assay on Vero cells.

555

556 **Bone-marrow derived macrophages.** Bone marrow-derived macrophages (BMDM)
557 were generated from CC mice. Mice were euthanized and femurs and tibias were isolated
558 from hind limbs. Bone marrow was flushed out with 10 ml DMEM delivered via syringe
559 with 25G ½ inch needle. Bone marrow was pooled and pipetted up and down with a 5 ml
560 serological pipette to break up large chunks. Cells were pelleted by centrifugation at 1500
561 rpm for 5 min at 4°C. Supernatants were removed and cell pellets were resuspended in
562 ACK Red Blood Cell Lysis Buffer containing 150 mM NH₄Cl, 10 mM KHCO₃, and 0.1 mM
563 EDTA pH 7.3, and incubated for 2-3 minutes. Cells were resuspended in DMEM
564 containing 10% heat-inactivated FBS and then pelleted by centrifugation at 1500 rpm for
565 5 min at 4°C. Cell pellets were resuspended in DMEM containing 10% heat-inactivated
566 FBS and counted. 12-well non-TC treated plates were seeded with 1.5×10^5 cells/well in
567 1 ml of DMEM containing L-Glutamine, NaPyr, Pen/Strep, 10% heat-inactivated FBS, and
568 40 ng/ml mouse M-CSF (BioLegend 576406) and incubated for 7 days at 37°C with 5%
569 CO₂. BMDMs were infected at an MOI of 0.01 with POWV strain MB5/12 or WNV strain
570 NY2000 in DMEM containing L-Glutamine, NaPyr, Pen/Strep, 10% heat-inactivated FBS,
571 and 20 ng/ml mouse M-CSF. After 1 hour, inoculum was removed and replaced with fresh

572 media and plates were incubated at 37°C with 5% CO₂. After 4, 24, 48, or 72 hours,
573 supernatants were collected and titered by focus-forming assay on Vero cells.

574

575 **Measurement of Viremia.** Blood was collected from mice by submandibular bleed or
576 terminal cardiac puncture in serum separator tubes (BD). Serum was separated by
577 centrifugation for 8000 rpm for 4 min and stored at -80°C until RNA isolation. RNA was
578 extracted with the Viral RNA Mini Kit (Qiagen). Viral RNA levels were determined by
579 TaqMan one-step qRT-PCR on a CFX96 Touch Real-Time PCR Detection System
580 (BioRad) using standard cycling conditions. Viremia is expressed on a Log₁₀ scale as
581 copies per ml based on a standard curve produced using serial 10-fold dilutions of a DNA
582 plasmid containing a 400 bp gBlock (Integrated DNA Technologies) encoding a portion
583 of the viral envelope (E) protein sequence. All primers and probes were purchased from
584 Integrated DNA Technologies. Primers used to detect POWV MB5/12 were: forward,
585 GAAGCTGAAAGGCACAAC TTAC; reverse, CACCTCCATGACCACTGTATC; and
586 probe, AAGAGTTCCTGTGGACAGTGGTCA. Primers used to detect WNV NY2000
587 were: forward, TCAGCGATCTCTCCACCAAAG; reverse,
588 GGGTCAGCACGTTGTCATTG; and probe, TGCCCGACCATGGGAGAAGCTC.
589 Primers used to detect JEV Nakayama were: forward, CAGCGTGGAGAACAGAGAA;
590 reverse, TGTGACCCAAGAGCAACAA; and probe,
591 CATGGAATTGAAAGAGGCGCACGC.

592

593 **Tissue Titers.** Nine to twelve-week-old male and female mice were infected with 100
594 FFU of POWV strain MB5/12. At 3 or 7 dpi, mice were bled by cardiac puncture, perfused

595 with 20 ml of PBS, and tissues were harvested. Brains and spleens were collected into 2
596 ml screwcap tubes containing 1 ml of DMEM supplemented with 2% heat-inactivated FBS
597 and homogenizer beads. Tissues were stored at -80°C until processing. Tissues were
598 thawed and homogenized using a MagNA Lyser (Roche) set to 6000 for 1 min.
599 Homogenates were titered by plaque assay on Vero cells. Serial 10-fold dilutions of tissue
600 homogenates were applied to Vero cells in 6-well plates and incubated at 37°C with 5%
601 CO₂. After 1 hour, cells were overlaid with 1% methylcellulose in minimum essential
602 medium Eagle (MEM) containing 2% heat-inactivated FBS. Following incubation for 6
603 days, plates were fixed with 2% paraformaldehyde overnight at room temperature. Fixed
604 plates were stained with 1% crystal violet in 20% ethanol, washed with tap water, and
605 plaques were counted manually.

606

607 **Data analysis.** Data were analyzed with GraphPad Prism software. Growth curves were
608 analyzed by two-way ANOVA to assess the impact of time and CC line on viral replication,
609 compared to CC019-Oas1b^{del} (Fig.1E-F) or CC045 (Fig. 5). Viremia was compared to
610 CC045 mice by one-way ANOVA (Fig. 4). Tissue titers were analyzed by two-way ANOVA
611 to assess the impact of time and CC line on viral loads, compared to CC045 (Fig. 6). A p
612 value of < 0.05 was considered statistically significant.

613

614 **ACKNOWLEDGEMENTS**

615 This work was supported by R21 AI145377 (H.M.L), R01 AI170625 (H.M.L.), and U19
616 AI100625 (M.T.H. and M.T.F.), by start-up funds from the UNC Lineberger
617 Comprehensive Cancer Center and Department of Microbiology & Immunology, and by

618 Systems Genetics Pilot Projects from the UNC School of Medicine. B.A.J. was supported
619 by F32 AI161786. K.E.N. was supported by T32 AI007419. We appreciate the support of
620 the Systems Genetics Core Facility and Mutant Mouse Research and Resource Center
621 and we also acknowledge Dr. Dale Cowley and the UNC Animal Models Core Facility for
622 generating the CC019-Oas1b^{del} mice.

623
624 **REFERENCES**
625

- 626 1. Gould EA, Solomon T. 2008. Pathogenic flaviviruses. Lancet 371:500-9.
- 627 2. Solomon T. 2004. Flavivirus encephalitis. N Engl J Med 351:370-8.
- 628 3. Hermance ME, Thangamani S. 2017. Powassan Virus: An Emerging Arbovirus of
629 Public Health Concern in North America. Vector Borne Zoonotic Dis 17:453-462.
- 630 4. Paules CI, Marston HD, Bloom ME, Fauci AS. 2018. Tickborne Diseases -
631 Confronting a Growing Threat. N Engl J Med 379:701-703.
- 632 5. McLean DM, Donohue WL. 1959. Powassan virus: isolation of virus from a fatal
633 case of encephalitis. Can Med Assoc J 80:708-11.
- 634 6. Beasley DW, Suderman MT, Holbrook MR, Barrett AD. 2001. Nucleotide
635 sequencing and serological evidence that the recently recognized deer tick virus
636 is a genotype of Powassan virus. Virus Res 79:81-9.
- 637 7. Kuno G, Artsob H, Karabatsos N, Tsuchiya KR, Chang GJ. 2001. Genomic
638 sequencing of deer tick virus and phylogeny of powassan-related viruses of North
639 America. Am J Trop Med Hyg 65:671-6.
- 640 8. Ebel GD, Spielman A, Telford SR. 2001. Phylogeny of North American Powassan
641 virus. J Gen Virol 82:1657-1665.
- 642 9. Ebel GD. 2010. Update on Powassan virus: emergence of a North American tick-
643 borne flavivirus. Annu Rev Entomol 55:95-110.
- 644 10. Bigham AW, Buckingham KJ, Husain S, Emond MJ, Bofferding KM, Gildersleeve
645 H, Rutherford A, Astakhova NM, Perelygin AA, Busch MP, Murray KO, Sejvar JJ,
646 Green S, Kriesel J, Brinton MA, Bamshad M. 2011. Host genetic risk factors for
647 West Nile virus infection and disease progression. PLoS One 6:e24745.
- 648 11. Barkhash AV, Babenko VN, Voevoda MI, Romaschenko AG. 2016. Association of
649 IL28B and IL10 gene polymorphism with predisposition to tick-borne encephalitis
650 in a Russian population. Ticks Tick Borne Dis 7:808-812.
- 651 12. Barkhash AV, Perelygin AA, Babenko VN, Brinton MA, Voevoda MI. 2012. Single
652 nucleotide polymorphism in the promoter region of the CD209 gene is associated
653 with human predisposition to severe forms of tick-borne encephalitis. Antiviral Res
654 93:64-8.
- 655 13. Barkhash AV, Voevoda MI, Romaschenko AG. 2013. Association of single
656 nucleotide polymorphism rs3775291 in the coding region of the TLR3 gene with
657 predisposition to tick-borne encephalitis in a Russian population. Antiviral Res
658 99:136-8.

659 14. Kindberg E, Mickiene A, Ax C, Akerlind B, Vene S, Lindquist L, Lundkvist A,
660 Svensson L. 2008. A deletion in the chemokine receptor 5 (CCR5) gene is
661 associated with tickborne encephalitis. *J Infect Dis* 197:266-9.

662 15. Mickiene A, Pakalniene J, Nordgren J, Carlsson B, Hagbom M, Svensson L,
663 Lindquist L. 2014. Polymorphisms in chemokine receptor 5 and Toll-like receptor
664 3 genes are risk factors for clinical tick-borne encephalitis in the Lithuanian
665 population. *PLoS One* 9:e106798.

666 16. Cahill ME, Conley S, DeWan AT, Montgomery RR. 2018. Identification of genetic
667 variants associated with dengue or West Nile virus disease: a systematic review
668 and meta-analysis. *BMC Infect Dis* 18:282.

669 17. Glass WG, McDermott DH, Lim JK, Lekhong S, Yu SF, Frank WA, Pape J,
670 Cheshier RC, Murphy PM. 2006. CCR5 deficiency increases risk of symptomatic
671 West Nile virus infection. *J Exp Med* 203:35-40.

672 18. Lim JK, McDermott DH, Lisco A, Foster GA, Krysztof D, Follmann D, Stramer SL,
673 Murphy PM. 2010. CCR5 deficiency is a risk factor for early clinical manifestations
674 of West Nile virus infection but not for viral transmission. *J Infect Dis* 201:178-85.

675 19. Webster LT. 1937. Inheritance of Resistance of Mice to Enteric Bacterial and
676 Neurotropic Virus Infections. *J Exp Med* 65:261-86.

677 20. Perelygin AA, Scherbik SV, Zhulin IB, Stockman BM, Li Y, Brinton MA. 2002.
678 Positional cloning of the murine flavivirus resistance gene. *Proc Natl Acad Sci U S*
679 *A* 99:9322-7.

680 21. Mashimo T, Lucas M, Simon-Chazottes D, Frenkiel MP, Montagutelli X, Ceccaldi
681 PE, Deubel V, Guenet JL, Despres P. 2002. A nonsense mutation in the gene
682 encoding 2'-5'-oligoadenylate synthetase/L1 isoform is associated with West Nile
683 virus susceptibility in laboratory mice. *Proc Natl Acad Sci U S A* 99:11311-6.

684 22. Webster LT. 1933. Inherited and Acquired Factors in Resistance to Infection : I.
685 Development of Resistant and Susceptible Lines of Mice through Selective
686 Breeding. *J Exp Med* 57:793-817.

687 23. Casals J, Schneider HA. 1943. Natural Resistance and Susceptibility to Russian
688 Spring-Summer Encephalitis in Mice. *Proceedings of the Society for Experimental*
689 *Biology and Medicine* 54:201-202.

690 24. Webster LT, Clow AD. 1936. Experimental Encephalitis (St. Louis Type) in Mice
691 with High Inborn Resistance : A Chronic Subclinical Infection. *J Exp Med* 63:827-
692 45.

693 25. Webster LT, Johnson MS. 1941. Comparative Virulence of St. Louis Encephalitis
694 Virus Cultured with Brain Tissue from Innately Susceptible and Innately Resistant
695 Mice. *J Exp Med* 74:489-94.

696 26. Sawyer WA, Lloyd W. 1931. The Use of Mice in Tests of Immunity against Yellow
697 Fever. *J Exp Med* 54:533-55.

698 27. Lynch CJ, Hughes TP. 1936. The Inheritance of Susceptibility to Yellow Fever
699 Encephalitis in Mice. *Genetics* 21:104-12.

700 28. Brinton MA, Perelygin AA. 2003. Genetic resistance to flaviviruses. *Adv Virus Res*
701 60:43-85.

702 29. Collaborative Cross C. 2012. The genome architecture of the Collaborative Cross
703 mouse genetic reference population. *Genetics* 190:389-401.

704 30. Noll KE, Ferris MT, Heise MT. 2019. The Collaborative Cross: A Systems Genetics
705 Resource for Studying Host-Pathogen Interactions. *Cell Host Microbe* 25:484-498.

706 31. Srivastava A, Morgan AP, Najarian ML, Sarsani VK, Sigmon JS, Shorter JR,
707 Kashfeen A, McMullan RC, Williams LH, Giusti-Rodriguez P, Ferris MT, Sullivan
708 P, Hock P, Miller DR, Bell TA, McMillan L, Churchill GA, de Villena FP. 2017.
709 Genomes of the Mouse Collaborative Cross. *Genetics* 206:537-556.

710 32. Graham JB, Swarts JL, Mooney M, Choonoo G, Jeng S, Miller DR, Ferris MT,
711 McWeeney S, Lund JM. 2017. Extensive Homeostatic T Cell Phenotypic Variation
712 within the Collaborative Cross. *Cell Rep* 21:2313-2325.

713 33. Leist SR, Baric RS. 2018. Giving the Genes a Shuffle: Using Natural Variation to
714 Understand Host Genetic Contributions to Viral Infections. *Trends Genet* 34:777-
715 789.

716 34. Cartwright HN, Barbeau DJ, Doyle JD, Klein E, Heise MT, Ferris MT, McElroy AK.
717 2022. Genetic diversity of collaborative cross mice enables identification of novel
718 rift valley fever virus encephalitis model. *PLoS Pathog* 18:e1010649.

719 35. Schafer A, Leist SR, Gralinski LE, Martinez DR, Winkler ES, Okuda K, Hawkins
720 PE, Gully KL, Graham RL, Scobey DT, Bell TA, Hock P, Shaw GD, Loome JF,
721 Madden EA, Anderson E, Baxter VK, Taft-Benz SA, Zweigart MR, May SR, Dong
722 S, Clark M, Miller DR, Lynch RM, Heise MT, Tisch R, Boucher RC, Pardo Manuel
723 de Villena F, Montgomery SA, Diamond MS, Ferris MT, Baric RS. 2022. A Multitrait
724 Locus Regulates Sarbecovirus Pathogenesis. *mBio* 13:e0145422.

725 36. Graham JB, Thomas S, Swarts J, McMillan AA, Ferris MT, Suthar MS, Treuting
726 PM, Ireton R, Gale M, Jr., Lund JM. 2015. Genetic diversity in the collaborative
727 cross model recapitulates human West Nile virus disease outcomes. *mBio*
728 6:e00493-15.

729 37. Green R, Wilkins C, Thomas S, Sekine A, Hendrick DM, Voss K, Ireton RC,
730 Mooney M, Go JT, Choonoo G, Jeng S, de Villena FP, Ferris MT, McWeeney S,
731 Gale M, Jr. 2017. Oas1b-dependent Immune Transcriptional Profiles of West Nile
732 Virus Infection in the Collaborative Cross. *G3 (Bethesda)* 7:1665-1682.

733 38. Elbahesh H, Jha BK, Silverman RH, Scherbik SV, Brinton MA. 2011. The Flvr-
734 encoded murine oligoadenylate synthetase 1b (Oas1b) suppresses 2-5A synthesis
735 in intact cells. *Virology* 409:262-70.

736 39. Kakuta S, Shibata S, Iwakura Y. 2002. Genomic structure of the mouse 2',5'-
737 oligoadenylate synthetase gene family. *J Interferon Cytokine Res* 22:981-93.

738 40. Kemenesi G, Banyai K. 2019. Tick-Borne Flaviviruses, with a Focus on Powassan
739 Virus. *Clin Microbiol Rev* 32.

740 41. Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, Marfin
741 AA, Solomon T, Tsai TF, Tsu VD, Ginsburg AS. 2011. Estimated global incidence
742 of Japanese encephalitis: a systematic review. *Bull World Health Organ* 89:766-
743 74, 774A-774E.

744 42. Heffelfinger JD, Li X, Batmunkh N, Grabovac V, Diorditsa S, Liyanage JB,
745 Pattamadilok S, Bahl S, Vannice KS, Hyde TB, Chu SY, Fox KK, Hills SL, Marfin
746 AA. 2017. Japanese Encephalitis Surveillance and Immunization - Asia and
747 Western Pacific Regions, 2016. *MMWR Morb Mortal Wkly Rep* 66:579-583.

748 43. Furuya-Kanamori L, Gyawali N, Mills DJ, Hugo LE, Devine GJ, Lau CL. 2022. The
749 Emergence of Japanese Encephalitis in Australia and the Implications for a
750 Vaccination Strategy. *Trop Med Infect Dis* 7.

751 44. Centers for Disease Control and Prevention. West Nile Virus: Final Cumulative
752 Maps & Data for 1999– 2020 [updated December 17, 2021].
753 <https://www.cdc.gov/westnile/statsmaps/cumMapsData.html>. Accessed

754 45. Lindquist L, Vapalahti O. 2008. Tick-borne encephalitis. *Lancet* 371:1861-71.

755 46. Heinz FX, Stiasny K, Holzmann H, Grgic-Vitek M, Kriz B, Essl A, Kundi M. 2013. Vaccination and tick-borne encephalitis, central Europe. *Emerg Infect Dis* 19:69-76.

756 47. Roesch F, Fajardo A, Moratorio G, Vignuzzi M. 2019. Usutu Virus: An Arbovirus
757 on the Rise. *Viruses* 11.

758 48. Cle M, Beck C, Salinas S, Lecollinet S, Gutierrez S, Van de Perre P, Baldet T,
759 Foulongne V, Simonin Y. 2019. Usutu virus: A new threat? *Epidemiol Infect*
760 147:e232.

761 49. Shives KD, Tyler KL, Beckham JD. 2017. Molecular mechanisms of
762 neuroinflammation and injury during acute viral encephalitis. *J Neuroimmunol*
763 308:102-111.

764 50. Milora KA, Rall GF. 2019. Interferon Control of Neurotropic Viral Infections. *Trends
765 Immunol* 40:842-856.

766 51. Klein RS, Hunter CA. 2017. Protective and Pathological Immunity during Central
767 Nervous System Infections. *Immunity* 46:891-909.

768 52. Klein RS, Garber C, Howard N. 2017. Infectious immunity in the central nervous
769 system and brain function. *Nat Immunol* 18:132-141.

770 53. Stone ET, Hassert M, Geerling E, Wagner C, Brien JD, Ebel GD, Hirsch AJ,
771 German C, Smith JL, Pinto AK. 2022. Balanced T and B cell responses are
772 required for immune protection against Powassan virus in virus-like particle
773 vaccination. *Cell Rep* 38:110388.

774 54. Santos RI, Hermance ME, Reynolds ES, Thangamani S. 2021. Salivary gland
775 extract from the deer tick, *Ixodes scapularis*, facilitates neuroinvasion by
776 Powassan virus in BALB/c mice. *Sci Rep* 11:20873.

777 55. Mlera L, Meade-White K, Saturday G, Scott D, Bloom ME. 2017. Modeling
778 Powassan virus infection in *Peromyscus leucopus*, a natural host. *PLoS Negl Trop
779 Dis* 11:e0005346.

780 56. Hermance ME, Thangamani S. 2015. Tick Saliva Enhances Powassan Virus
781 Transmission to the Host, Influencing Its Dissemination and the Course of Disease.
782 *J Virol* 89:7852-60.

783 57. Pesko KN, Torres-Perez F, Hjelle BL, Ebel GD. 2010. Molecular epidemiology of
784 Powassan virus in North America. *J Gen Virol* 91:2698-705.

785 58. Graham JB, Swarts JL, Wilkins C, Thomas S, Green R, Sekine A, Voss KM, Ireton
786 RC, Mooney M, Choonoo G, Miller DR, Treuting PM, Pardo Manuel de Villena F,
787 Ferris MT, McWeeney S, Gale M, Jr., Lund JM. 2016. A Mouse Model of Chronic
788 West Nile Virus Disease. *PLoS Pathog* 12:e1005996.

789 59. Cain MD, Salimi H, Diamond MS, Klein RS. 2019. Mechanisms of Pathogen
790 Invasion into the Central Nervous System. *Neuron* 103:771-783.

791

792

793 60. Lopalco L. 2010. CCR5: From Natural Resistance to a New Anti-HIV Strategy. Viruses 2:574-600.

794 61. Glass WG, Lim JK, Cholera R, Pletnev AG, Gao JL, Murphy PM. 2005. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. *J Exp Med* 202:1087-98.

795 62. Larena M, Regner M, Lobigs M. 2012. The chemokine receptor CCR5, a therapeutic target for HIV/AIDS antagonists, is critical for recovery in a mouse model of Japanese encephalitis. *PLoS One* 7:e44834.

796 63. Durrant DM, Daniels BP, Pasieka T, Dorsey D, Klein RS. 2015. CCR5 limits cortical viral loads during West Nile virus infection of the central nervous system. *J Neuroinflammation* 12:233.

797 64. Michlmayr D, Bardina SV, Rodriguez CA, Pletnev AG, Lim JK. 2016. Dual Function of Ccr5 during Langat Virus Encephalitis: Reduction in Neutrophil-Mediated Central Nervous System Inflammation and Increase in T Cell-Mediated Viral Clearance. *J Immunol* 196:4622-31.

798 65. Lim JK, Lisco A, McDermott DH, Huynh L, Ward JM, Johnson B, Johnson H, Pape J, Foster GA, Krysztof D, Follmann D, Stramer SL, Margolis LB, Murphy PM. 2009. Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. *PLoS Pathog* 5:e1000321.

799 66. Barkhash AV, Perelygin AA, Babenko VN, Myasnikova NG, Pilipenko PI, Romaschenko AG, Voevoda MI, Brinton MA. 2010. Variability in the 2'-5'-oligoadenylate synthetase gene cluster is associated with human predisposition to tick-borne encephalitis virus-induced disease. *J Infect Dis* 202:1813-8.

800 67. Soveg FW, Schwerk J, Gokhale NS, Cerosaletti K, Smith JR, Pairo-Castineira E, Kell AM, Forero A, Zaver SA, Esser-Nobis K, Roby JA, Hsiang TY, Ozarkar S, Clingan JM, McAnarney ET, Stone AE, Malhotra U, Speake C, Perez J, Balu C, Allenspach EJ, Hyde JL, Menachery VD, Sarkar SN, Woodward JJ, Stetson DB, Baillie JK, Buckner JH, Gale M, Jr., Savan R. 2021. Endomembrane targeting of human OAS1 p46 augments antiviral activity. *Elife* 10.

801 68. Danial-Farran N, Eghbaria S, Schwartz N, Kra-Oz Z, Bisharat N. 2015. Genetic variants associated with susceptibility of Ashkenazi Jews to West Nile virus infection. *Epidemiol Infect* 143:857-63.

802 69. Long D, Deng X, Singh P, Loeb M, Lauring AS, Seielstad M. 2016. Identification of genetic variants associated with susceptibility to West Nile virus neuroinvasive disease. *Genes Immun* 17:298-304.

803 70. Hoffmann HH, Schneider WM, Rozen-Gagnon K, Miles LA, Schuster F, Razooky B, Jacobson E, Wu X, Yi S, Rudin CM, MacDonald MR, McMullan LK, Poirier JT, Rice CM. 2021. TMEM41B Is a Pan-flavivirus Host Factor. *Cell* 184:133-148 e20.

804 71. Manet C, Roth C, Tawfik A, Cantaert T, Sakuntabhai A, Montagutelli X. 2018. Host genetic control of mosquito-borne Flavivirus infections. *Mamm Genome* 29:384-407.

805 72. Ferris MT, Aylor DL, Bottomly D, Whitmore AC, Aicher LD, Bell TA, Bradel-Tretheway B, Bryan JT, Buus RJ, Gralinski LE, Haagmans BL, McMillan L, Miller DR, Rosenzweig E, Valdar W, Wang J, Churchill GA, Threadgill DW, McWeeney SK, Katze MG, Pardo-Manuel de Villena F, Baric RS, Heise MT. 2013. Modeling

838 host genetic regulation of influenza pathogenesis in the collaborative cross. PLoS
839 Pathog 9:e1003196.

840 73. Gralinski LE, Ferris MT, Aylor DL, Whitmore AC, Green R, Frieman MB, Deming
841 D, Menachery VD, Miller DR, Buus RJ, Bell TA, Churchill GA, Threadgill DW, Katze
842 MG, McMillan L, Valdar W, Heise MT, Pardo-Manuel de Villena F, Baric RS. 2015. Genome Wide Identification of SARS-CoV Susceptibility Loci Using the
843 Collaborative Cross. PLoS Genet 11:e1005504.

844 74. Maurizio PL, Ferris MT, Keele GR, Miller DR, Shaw GD, Whitmore AC, West A,
845 Morrison CR, Noll KE, Plante KS, Cockrell AS, Threadgill DW, Pardo-Manuel de
846 Villena F, Baric RS, Heise MT, Valdar W. 2018. Bayesian Diallel Analysis Reveals
847 Mx1-Dependent and Mx1-Independent Effects on Response to Influenza A Virus
848 in Mice. G3 (Bethesda) 8:427-445.

849 75. Green R, Wilkins C, Thomas S, Sekine A, Ireton RC, Ferris MT, Hendrick DM,
850 Voss K, de Villena FP, Baric R, Heise M, Gale M, Jr. 2016. Identifying protective
851 host gene expression signatures within the spleen during West Nile virus infection
852 in the collaborative cross model. Genom Data 10:114-117.

853 76. Green R, Wilkins C, Thomas S, Sekine A, Ireton RC, Ferris MT, Hendrick DM,
854 Voss K, Pardo-Manuel de Villena F, Baric RS, Heise MT, Gale M, Jr. 2016. Transcriptional profiles of WNV neurovirulence in a genetically diverse
855 Collaborative Cross population. Genom Data 10:137-140.

856 77. Graham JB, Swarts JL, Menachery VD, Gralinski LE, Schafer A, Plante KS,
857 Morrison CR, Voss KM, Green R, Choonoo G, Jeng S, Miller DR, Mooney MA,
858 McWeeney SK, Ferris MT, Pardo-Manuel de Villena F, Gale M, Heise MT, Baric
859 RS, Lund JM. 2020. Immune Predictors of Mortality After Ribonucleic Acid Virus
860 Infection. J Infect Dis 221:882-889.

861 78. Montagutelli X, Prot M, Jouvion G, Levillayer L, Conquet L, Reyes-Gomez E,
862 Donati F, Albert M, van der Werf S, Jaubert J, Simon-Lorière E. 2021. A mouse-
863 adapted SARS-CoV-2 strain replicating in standard laboratory mice. bioRxiv
864 doi:10.1101/2021.07.10.451880:2021.07.10.451880.

865 79. Manet C, Simon-Loriere E, Jouvion G, Hardy D, Prot M, Conquet L, Flamand M,
866 Panthier JJ, Sakuntabhai A, Montagutelli X. 2020. Genetic Diversity of
867 Collaborative Cross Mice Controls Viral Replication, Clinical Severity, and Brain
868 Pathology Induced by Zika Virus Infection, Independently of Oas1b. J Virol 94.

869 80. Scherbik SV, Paranjape JM, Stockman BM, Silverman RH, Brinton MA. 2006. Rnase L plays a role in the antiviral response to West Nile virus. J Virol 80:2987-
870 99.

871 81. Brien JD, Lazear HM, Diamond MS. 2013. Propagation, quantification, detection,
872 and storage of West Nile virus. Curr Protoc Microbiol 31:15D 3 1-15D 3 18.

873 82. Zhao H, Fernandez E, Dowd KA, Speer SD, Platt DJ, Gorman MJ, Govero J,
874 Nelson CA, Pierson TC, Diamond MS, Fremont DH. 2016. Structural Basis of Zika
875 Virus-Specific Antibody Protection. Cell 166:1016-1027.

876 83. Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, Marri A,
877 Lachmi BE, Olshevsky U, Fremont DH, Pierson TC, Diamond MS. 2006. Antibody
878 recognition and neutralization determinants on domains I and II of West Nile Virus
879 envelope protein. J Virol 80:12149-59.

880
881
882
883

884

885 **FIGURE LEGENDS**

886

887 **Figure 1. Oas1b restricts pathogenesis of diverse neuroinvasive flaviviruses. A-D.**

888 Five to six-week-old male and female CC019, CC019-*Oas1b*^{del}, or C57BL/6J mice were
889 infected with 100 FFU of POWV strain LB (A), POWV DTV strain Spooner (B), WNV strain
890 NY2000 (C), or JEV strain Nakayama (D) by subcutaneous inoculation in the footpad and
891 lethality was monitored for 21 days. Data are combined from 4-5 experiments per virus.

892 E-F. Mouse embryo fibroblasts (MEFs) were harvested from the indicated mouse lines
893 for multistep growth curve analysis. MEFs were infected at an MOI of 0.01 with POWV
894 strain LB (E) or WNV strain NY2000 (F). Supernatants were collected at 4, 24, 48, or 72
895 hours post-infection and titered by focus-forming assay on Vero cells. Results shown are
896 the mean +/- SEM of 2-3 independent experiments performed in duplicate or triplicate.

897 Asterisks represent statistical significance (* p<0.05, ** p<0.01, *** p<0.001) by two-way
898 ANOVA compared to CC019-*Oas1b*^{del}. G-H. Nine to twelve-week-old C57BL/6J wild-type
899 or *Oas1g*^{-/-} male and female mice were infected with 100 FFU of POWV strain MB5/12
900 (G) or WNV strain NY2000 (H) by subcutaneous inoculation in the footpad and lethality
901 was monitored for 21 days.

902

903 **Figure 2. Host factors influence POWV pathogenesis across Oas1b-null**
904 **Collaborative Cross mouse lines.** Nine to twelve-week-old male and female mice were
905 infected with 100 FFU of POWV (strain LB) by subcutaneous inoculation in the footpad
906 and lethality was monitored for 21 days. Lines are ordered by percent survival and mean

907 time to death. N=34 C67BL/6 mice, 18 CC019-*Oas1b*^{del} mice, and 6-7 mice for other lines.

908 Data are combined from 9 experiments.

909

910 **Figure 3. Susceptibility phenotypes in Collaborative Cross mice are shared among**
911 **diverse neuroinvasive flaviviruses.** A-D. Nine to twelve-week-old male and female
912 mice from *Oas1b*-null CC lines were infected with 100 FFU of POWV strain MB5/12 (A),
913 WNV strain NY2000 (B), JEV strain Nakayama (C), or SLEV strain GHA-3 (D) by
914 subcutaneous inoculation in the footpad and lethality was monitored for 21 days. Data
915 are combined from 4-8 experiments per virus. E. Nine to twelve-week-old male mice from
916 *Oas1b*^{+/+} CC lines were infected with 100 FFU of POWV strain MB5/12 and lethality was
917 monitored for 21 days. Data represent a single experiment.

918

919 **Figure 4. Serum viral loads at 2 dpi do not correlate with susceptibility to**
920 **neuroinvasive flaviviruses.** Nine to twelve-week-old male and female mice were
921 infected with 100 FFU of POWV (A and B), WNV (C), or JEV (D) by subcutaneous
922 inoculation in the footpad. Mice were bled 2 dpi and viremia was assessed by qRT-PCR.
923 Asterisks represent statistical significance (* p<0.05, *** p<0.001) by one-way ANOVA
924 compared to CC045 (panels A, C, and D). CC lines in A, C, and D are all *Oas1b*-null; CC
925 lines in B are *Oas1b*^{+/+}. Open symbols denote surviving mice.

926

927 **Figure 5. Susceptibility to flavivirus disease is concordant with restriction of viral**
928 **replication in macrophages ex vivo.** Bone marrow-derived macrophages (BMDM) were
929 harvested from CC mice (CC045, CC071, and CC015) for multistep growth curve

930 analysis. BMDMs were infected at an MOI of 0.01 with POWV (A) or WNV (B).
931 Supernatants were collected at 4, 24, 48, or 72 hours post-infection and titered by focus-
932 forming assay on Vero cells. Results shown are the mean +/- SEM of 2-3 independent
933 experiments performed in duplicate or triplicate. Asterisks represent statistical
934 significance (* p<0.05, *** p<0.001) by two-way ANOVA compared to CC045.

935

936 **Figure 6. Reduced CNS viral loads correlate with POWV resistance.** Nine to twelve-
937 week-old male and female CC071 (susceptible) and CC045 (resistant) mice were infected
938 with 100 FFU of POWV (strain MB5/12) by subcutaneous inoculation in the footpad. A-D.
939 At the indicated time points, mice were perfused and tissues were harvested. A. Mice
940 were bled by cardiac puncture prior to perfusion and viremia was assessed by qRT-PCR.
941 B-D. Spleen, brain, and spinal cord homogenates were titered by plaque assay on Vero
942 cells. E-F. Mice were serially bled 2, 3, and 4 dpi and viremia was assessed by qRT-PCR.
943 Asterisks represent statistical significance (* p<0.05, *** p<0.001) by two-way ANOVA.

944
945

946 **Table 1: Collaborative Cross mouse lines used in this study.**

CC Line	Legend Symbol	<i>Oas1b</i> allele	POVW LB (Fig. 2)		POVW MB5/12 (Fig. 3)	
			% Lethality	MTD	% Lethality	MTD
CC001	●	Null	83	12.7	-	-
CC003	●	WSB	-	-	0	N/A
CC004	■	PWK	-	-	0	N/A
CC006	★	Null	100	8.8	56	15.9
CC013	■	Null	100	9.3	-	-
CC015	●	Null	100	8.3	100	9.3
CC016	■	Null	100	10.3	-	-
CC019	■	WSB	-	-	-	-
CC019- <i>Oas1b</i> ^{del}	■	Null	78	12.9	38	16.5
CC021	■	Null	100	9.2	-	-
CC026	▲	Null	100	9.5	-	-
CC027	■	Null	83	10.8	-	-
CC030	★	WSB	-	-	0	N/A
CC043	■	Null	67	13.2	-	-
CC045	●	Null	0	N/A	22	18.4
CC049	■	Null	100	10.2	-	-
CC051	■	Null	100	12.7	-	-
CC057	▼	Null	50	16.5	0	N/A
CC061	■	Null	100	9.1	-	-
CC062	■	Null	67	15.2	-	-
CC071	■	Null	100	8.2	100	9.1

947

948 CC: Collaborative Cross

949 MTD: mean time to death (days)

950 -: not done

951 N/A: not applicable